Related Experiment Videos
[Double heart valve replacement disclosing antiphospholipid syndrome]
E Hachulla1, D Bataille, A Janin
1Clinique Médicale A, Hôpital Claude Huriez, Lille.
La Revue De Medecine Interne
|May 1, 1992
Summary
Systemic lupus erythematosus (SLE) can cause heart valve damage, often linked to antiphospholipid antibodies. This case highlights Libman-Sachs endocarditis and the potential overlap between SLE and antiphospholipid syndrome.
Area of Science:
- Cardiology
- Rheumatology
- Pathology
Background:
- Systemic lupus erythematosus (SLE) can affect heart valves, but severe complications requiring valve replacement are rare.
- Antiphospholipid antibodies are known to increase the risk of thrombotic events and pregnancy complications.
Observation:
- A patient with SLE underwent aortic and mitral valve replacement.
- Post-surgery, antiphospholipid antibodies were detected, alongside four American College of Rheumatology (ARA) criteria for SLE.
- Histopathology confirmed Libman-Sachs endocarditis, a specific form of verrucous endocarditis associated with autoimmune diseases.
Findings:
- The patient's heart valve lesions were attributed to Libman-Sachs endocarditis.
- The presence of antiphospholipid antibodies suggests a significant role in the patient's cardiac and vascular complications.
- A notable overlap exists between the diagnostic criteria for SLE and primary antiphospholipid syndrome.
Implications:
- Antiphospholipid antibodies may be a key factor in the development of heart valve lesions in SLE patients.
- Heart valve disease could serve as an initial clinical manifestation of antiphospholipid syndrome.
- This case underscores the importance of screening for antiphospholipid antibodies in SLE patients with cardiac involvement.